Live Breaking News & Updates on Viloxazine

Stay informed with the latest breaking news from Viloxazine on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Viloxazine and stay connected to the pulse of your community

FDA OKs first new ADHD drug in over a decade for children

FDA OKs first new ADHD drug in over a decade for children
LINDA A. JOHNSON, Associated Press
April 5, 2021
FacebookTwitterEmail
This undated image provided by Supernus Pharmaceuticals in April 2021 shows bottles for different dosages of the drug Qelbree. On Friday, April 2, 2021, the U.S. Food and Drug Administration approved the medication for treating attention deficit hyperactivity disorder in children ages six through 17. (Supernus Pharmaceuticals via AP)AP
U.S. regulators have approved the first new drug in over a decade for children with ADHD, which causes inattention, hyperactivity and impulsivity.
The Food and Drug Administration late Friday OK’d Qelbree (KELL’-bree) for treating attention deficit hyperactivity disorder in children ages 6 to 17. It comes as a capsule that’s taken daily.

Maryland , United-states , Baltimore , American , Lindaa-johnson , Davidw-goodman , Johns-hopkins-school-of-medicine , Psychiatric-associates , Health-science-department , Supernus-pharmaceuticals-of-rockville , Supernus-pharmaceuticals